[
    [
        {
            "time": "2023-10-17",
            "original_text": "Amneal (AMRX) Down on Guidance Update & Restructuring Plan",
            "features": {
                "keywords": [
                    "Amneal",
                    "Guidance Update",
                    "Restructuring Plan"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 6,
                "Duration": 2,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Amgen and Novartis drop Alzheimer's-prevention study after patients worsened",
            "features": {
                "keywords": [
                    "Amgen",
                    "Novartis",
                    "Alzheimer's-prevention",
                    "patients worsened"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 1,
                "Importance": 9,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Signature Select Canadian Fund's Top 6 Buys",
            "features": {
                "keywords": [
                    "Signature Select",
                    "Canadian Fund",
                    "Top Buys"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "funds"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Amgen, Novartis abandon two Alzheimer’s drug studies",
            "features": {
                "keywords": [
                    "Amgen",
                    "Novartis",
                    "Alzheimer’s",
                    "drug studies"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 1,
                "Importance": 9,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill",
            "features": {
                "keywords": [
                    "Glaxo",
                    "HIV Pill",
                    "Dovato",
                    "Two-Drug",
                    "Three-Drug"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]